Ticker Short Interest

BOLT Short Interest Intelligence

Bolt Biotherapeutics positioning pressure, squeeze risk, bearish conviction, crowding, days to cover, and price-positioning divergence.

Latest settlement 30 Jun 2026 Crowded Short

Crowded Short

Bearish Exhaustion Watch

BOLT is classified as Crowded Short. Latest reported short interest is 16.7K shares; short interest changed -38.7%, price moved -6.2% since the previous report, short interest is in the 71th percentile, and days to cover is in the 71th percentile. Trend context is improving.

Setup Score71/100Crowded Short
Reported Short Interest16.7K-38.7% vs prior report
Days To Cover1.0071.43 percentile
Price Reaction-6.2%since previous short report
Squeeze Pressure50crowding, trend, and pressure
Bearish Conviction38shorts adding into weakness

Reported Short Interest

2026-03-31 to 2026-06-30

Days To Cover

liquidity pressure

Short Interest Change

report-to-report

Price Context

2026-03-20 to 2026-06-26

Squeeze Radar

50

Elevated short interest becomes most interesting when price strength forces shorts to defend or cover.

Bearish Conviction

38

Rising short interest alongside weak trend can mean the bearish trade is being reinforced, not trapped.

Crowding

71

Latest short interest is 16.7K shares and days to cover is 1.00.

Divergence

54

Short interest fell while price fell. Shorts are covering despite weak price action, which can suggest the easy bearish pressure may be fading.

Report History

BOLT Short Interest Ledger

Most recent first
SettlementShort interestPreviousChangeDays coverAverage volume
30 Jun 2026 16698 27250 -38.7% 1.00 39560
15 Jun 2026 27250 13125 107.6% 1.10 24781
29 May 2026 13125 12126 8.2% 1.00 34638
15 May 2026 12126 6999 73.3% 1.00 23966
30 Apr 2026 6999 22704 -69.2% 1.00 33057
15 Apr 2026 22704 4987 355.3% 1.04 21902
31 Mar 2026 4987 908 449.2% 1.00 16938

Short interest is delayed, reported on a periodic schedule, and may be revised. The dashboard is research context only and does not prove real-time short activity.